Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. RESULTS: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. CONCLUSIONS: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the earlier ENHANCE trial could not confirm that an addition of ezetimibe to statins significantly reduces intima-media thickness in patients with familial hypercholesterolemia, the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
In the citing paper
“the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationBots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationBuchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Cited by
Items 901–1,000 of 1,000
Attainment of combined optimal lipid values: a paradigm shift in the management of dyslipidemia
Cziraky, M. J., & Thomas, T. F. (2010) · Clinical Lipidology · doi:10.2217/clp.10.35 · Cited by 2
Viljoen, A., & Wierzbicki, A. S. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.53 · Cited by 2
Statins and Cancer: A Potential Link?
Thompson, J. S., Sood, A. K., & Arora, R. R. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31819df9cd · Cited by 2
“have an additive effect that is better than either drug alone for lowering total cholesterol levels.(5,6) Statins (ie, simvastatin) are a form of lipid-lowering”
BackgroundReynolds, T. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02218.x · Cited by 3
Bays, H. E. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.03.1993 · Cited by 2
Established and Emerging Approaches for the Management of Dyslipidaemia
Norata, G. D. (2012) · Scientifica · doi:10.6064/2012/482423 · Cited by 3
“Giuseppe Danilo Norata1, 2, 3 1Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano 20122 Milan, Italy 2Center for the Study of Atherosclerosis, Società Italiana Studio Aterosclerosi, Ospedale Bassini, 20092 Cinisello Balsamo, Italy 3Centre for Diabetes, e Blizard Institute, Barts…”
BackgroundAnother clinical evidence straw on the $4 billion ezetimibe camel's back
Taylor, A. J. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.05.028 · Cited by 2
“West’s study on atheroscleosis in humans is now the third such study, each of which either ailed to show any effect of ezetimibe over statin monotherapy [3], r to be inferior to alternative forms of combination therapy [4].”
BackgroundInfluentialPasquali, S. K., & Li, J. S. (2008) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.819235 · Cited by 2
Recent cholesterol-lowering drug trials: New data, new questions
de Lorgeri, M., & Salen, P. (2010) · Journal of Lipid Nutrition · doi:10.4010/jln.19.65 · Cited by 2
Lipid management in Type 2 diabetes: the case for combination therapy?
Saely, C. H., Drexel, V., Vonbank, A., & Drexel, H. (2011) · Therapy · doi:10.2217/thy.11.5 · Cited by 2
Singh, M., Chin, S. H., Giles, P. D., Crothers, D., Al-Allaf, K., & Khan, J. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328338978e · Cited by 3
The Failure of Vytorin and Statins to Improve Cardiovascular Health: Bad Cholesterol or Bad Theory?
Peskin, B. S., Sim, D., & Carter, M. J. (2008) · Cited by 2
Might ezetimibe be considered an expensive placebo?
Mascitelli, L., & Goldstein, M. R. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.150 · Cited by 2
Update on the Pharmacologic Agents for Dyslipidemia
Lee, S. (2015) · Journal of Korean Diabetes · doi:10.4093/jkd.2015.16.4.269 · Cited by 2
Pharmacotherapy Using Cardiovascular Agents: Focus on the Top 200 Drugs
Schnepp, A. R., & Nykamp, D. L. (2010) · Journal of Pharmacy Technology · doi:10.1177/875512251002600406 · Cited by 2
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Gersh, B. J. (2009) · Yearbook of Cardiology · doi:10.1016/s0145-4145(09)79523-1 · Cited by 2
Krysiak, R. G., Żmuda, W., Marek, B., & Okopień, B. (2014) · Endokrynologia Polska · doi:10.5603/ep.2014.0037 · Cited by 2
Das ABC der medizinischen Statistik: Klinische Studien lesen und verstehen
Labenz, J., & Kunz, C. U. (2010) · Der Internist · doi:10.1007/s00108-010-2581-x · Cited by 2
Advances in Acute Coronary Syndrome Management
White, H. D. (2012) · doi:10.2217/9781780840864 · Cited by 2
Strategies for the use of nonstatin therapies
Pirillo, A., Norata, G. D., & Catapano, A. L. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000459 · Cited by 2
FAMILIAL HYPERCHOLESTEROLEMIA: DIAGNOSTIC ISSUES AND THERAPEUTIC POSSIBILITIES
Зафираки, В. К., Муратович, Н. А., & Kosmacheva, E. D. (2019) · Кубанский научный медицинский вестник · doi:10.25207/1608-6228-2019-26-1-175-186 · Cited by 2
Physiological and Laboratory Markers of Drug Effect
Woodcock, J., Atkinson, A. J., & Rolan, P. E. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385471-1.00018-0 · Cited by 2
Dayspring, T. D., & Pokrywka, G. S. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_13 · Cited by 2
Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation?
Silvino, J. P. D. P., Carvalho, M. G., Reis, E. A., Mota, A. P. L., Gomes, K. B., Duarte, R. C. F., Guimarães, M. C., de Sousa, M. C. R., Azevedo, P. S., & Silva, I. D. F. O. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.02.002 · Cited by 2
Benetos, G., Galanakos, S., Koutagiar, I. P., Skoumas, I., Oikonomou, G., Drakopoulou, M. I., Karmpalioti, M., Katsi, V. K., Tsioufis, C. P., & Toutouzas, K. P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215008 · Cited by 2
“It has been shown that statin therapy lowers CRP and/or circulating pro-inflammatory cytokines’ levels in patients with hypercholesterolemia [21,22] and familial combined hyperlipidemia [23].”
BackgroundDiniz, E. T., & Bandeira, F. A. F. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_40 · Cited by 3
Conroy, R., Mackie, S. A., & Boney, C. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_32 · Cited by 2
Factors Affecting Consumers' Responses to Direct-to-Consumer Advertising.
Schueler, K. R. (2008) · Deep Blue (University of Michigan) · Cited by 2
Hyperlipidemia effects on clinical indexes of stroke in Japanese patients
Ogushi, Y., Haruki, Y., Shibata, T., Kobayashi, S., & JSSRS Group (2010) · Nosotchu · doi:10.3995/jstroke.32.242 · Cited by 2
An Assessment of the New Lipid Screening Guidelines
Steiner, M. J., Brown, W. D., & Liles, E. A. (2008) · PEDIATRICS · doi:10.1542/peds.2008-2103 · Cited by 2
Twenty-five years of statins: where do we go from here?
Gotto, A. M., & Moon, J. E. (2015) · Clinical Lipidology · doi:10.2217/clp.14.62 · Cited by 3
Lahoz, C., Mostaza, J. M., Martín, M. Á. S., Iglesias, M. F., Vargas, M. F., García, Á., Peraira, R., & Laguna, F. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.02.052 · Cited by 2
Percutaneousl US approach to diagnosis and treatment of atherosclerosis
Nishino, M. (2010) · Choonpa Igaku · doi:10.3179/jjmu.37.469 · Cited by 2
Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?
Steiner, G. A. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283189c2b · Cited by 3
History of the cholesterol hypothesis in Britain
Thompson, G. R. (2009) · QJM · doi:10.1093/qjmed/hcp098 · Cited by 2
How to Use Ezetimibe as an Anti-Atherogenic Agent via Inhibition of Rho-Kinase
Noma, K., & Higashi, Y. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0780 · Cited by 2
Are Statin Effects Mediated Through, or in Spite of, Their Cholesterol-lowering Action?
Mascitelli, L., Pezzetta, F., & Goldstein, M. R. (2009) · Angiology · doi:10.1177/0003319708330527 · Cited by 2
Hildemann, S. K., Barho, C., Karmann, B., Darius, H., & Bode, C. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802381406 · Cited by 2
Costa, J. A., Rodilla, E., Pérez-Lahiguera, F. J., Miralles, A., González, C., & Pascual, J. M. (2009) · Revista Clínica Española · doi:10.1016/s0014-2565(09)72513-5 · Cited by 2
Roberts, W. C. (2009) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2009.11928510 · Cited by 2
Wierzbicki, A. S. (2014) · Cardiogenetics · doi:10.4081/cardiogenetics.2014.4672 · Cited by 1
Cholesterol Absorption Inhibitor Ezetimibe: Risk–Benefits and Role in Treating Dyslipidemias
Yamashita, S., Masuda, D., & Matsuyama, A. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_28 · Cited by 1
Konečný, L., Hrubša, M., Karlíčková, J., Carazo, A., Javorská, L., Matoušová, K., Krčmová, L. K., Blaha, V., Blaha, M., & Mladěnka, P. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07455-y · Cited by 1
“The combination of statins and ezetimibe is more advantageous and results in an about 15% reduction of LDL-C in FH [26, 29].”
BackgroundJiao, P., Yang, N., Jia, Q., Fan, B., Feng, K., Yu, J., & Zhao, S. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1552085 · Cited by 1
Tomlinson, B. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642210 · Cited by 2
“Early clinical trials with ezetimibe did not show benefits in effects on carotid intima-media thickness (CIMT) or aortic stenosis [79,80].”
Sánchez, R. G., Bravo, S. P., Anaya, V. S., Castellano, S. M., Pérez, I. M., & Gámiz, J. L. P. (2026) · Romanian Journal of Preventive Medicine · doi:10.3390/rjpm4010002 · Cited by 1
Plaque regression: Risk status or ApoB exposure?
Lechner, K., Lechner, B., & Weingärtner, O. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120719 · Cited by 1
Lipids, Atherogenic Dyslipidemia, and Therapy
Levine, T. B., & Levine, A. B. (2012) · Wiley eBooks · doi:10.1002/9781118480045.ch13 · Cited by 2
Ehlers, M. R. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.3.221 · Cited by 1
Baron, M. (2003) · PubMed · Cited by 1
Calderon, H., Carvalho, A. J. P., Oliveira, I. C. R., Soares, E. A., Loyola, Y. C. S., dos Santos, L., Messora, L. B., Pereira, J. E. G., Incerpi, E. K., Lobão, P. H. O. A., et al. (2011) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Diabète de type 2: prise en charge efficace du risque vasculaire
Larger, É., Nobécourt, E., Rotariu, M., Radu, A., & Boîtard, C. (2009) · Sang thrombose vaisseaux · doi:10.1684/stv.2009.0413 · Cited by 1
“Pour ce qui est de l’ézétimibe, les résultats de l’étude ENHANCE [37], discutés et décriés, mais en dehors du contexte du diabète n’incitent pas à l’optimisme.”
Schuchert, A. (2008) · Der Kardiologe · doi:10.1007/s12181-008-0103-z · Cited by 1
Meaney, A., Solache, G., Macías, V. M. R., Izaguirre-Gutiérrez, F., Domínguez-Borgúa, A., & Meaney, E. (2015) · Cardiovascular and Metabolic Science · Cited by 1
Pérez‐Martínez, P., & Pérez‐Jiménez, F. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.02.018 · Cited by 1
Cardiopathie ischémique : le point sur le traitement pharmacologique en 2008
François, P. (2008) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(08)71666-3 · Cited by 1
Nuevas alternativas farmacológicas en dislipidemias
Eckel, R. H. (2009) · Medwave · doi:10.5867/medwave.2009.05.3915 · Cited by 1
Elis, A. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.39 · Cited by 1
Effect of Ezetimibe on Carotid Intimal Thickness: The VYCTOR Study
Farmer, J. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0088-5 · Cited by 1
“However, considerable controversy was generated following the negative results of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression study (ENHANCE) [3].”
BackgroundThe IMPROVE-IT trial: current status and potential clinical implications of ezetimibe
Akerström, F. O., & Padial, L. R. (2011) · Clinical Investigation · doi:10.4155/cli.10.14 · Cited by 1
A tool for evaluating the potential for cost-effective outcomes measurement
Somasekhar, M. M., Bove, Rausch, C., Degnan, J., Thomas-King, C., & Meyer, A. (2012) · International Journal of General Medicine · doi:10.2147/ijgm.s30546 · Cited by 1
Koie, M., Kondo, Y., Santou, T., Kitamoto, Y., Morita, S., Yamasaki, M., Fukushima, M., Inagaki, N., & Yasuda, K. (2013) · Diabetology International · doi:10.1007/s13340-013-0152-9 · Cited by 1
Plant stanol consumption for cardiovascular health: what do we know about efficacy and safety?
Gylling, H., & Miettinen, T. A. (2010) · Clinical Lipidology · doi:10.2217/clp.10.62 · Cited by 1
A review of trials evaluating nonstatin lipid-lowering therapies
Ansell, B. J. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0010-1 · Cited by 1
Roberts, W. C., Gotto, A. M., Guyton, J. R., LaRosa, J. C., & Viggiani, R. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.09.023 · Cited by 1
Prevención secundaria en enfermedad cardiovascular
Carratalà, F. R., Juan, G. F., Flores, I. S., Campos, S. T., Castellanos, J. G., & Berna, A. (2010) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(10)70305-4 · Cited by 3
Lands, B. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-215-5_2 · Cited by 1
Mipomersen: Pharmacology, Clinical Trials and Its Potential Role in Therapy
Evans, J. D., & Shelton, D. A. (2013) · Advances in Diabetes and Metabolism · doi:10.13189/adm.2013.010104 · Cited by 1
Use of Drugs in the Primary Prevention of Arterial Hypertension and Dyslipidemia
González‐Juanatey, J. R., & Ramos, P. M. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(08)60234-0 · Cited by 1
“Major Coronary Disease 30 (34-27) Coronary Revascularization 27 (20-34) Stroke 8 (4-12) Major Vascular Disease 48 (39-57) 30”
BackgroundAttainment of Goal and Normalized Lipid Levels With Lipid-Modifying Therapy in Malaysia
Hsu, T.-Y., Chirovsky, D. R., Moy, F. M., & Ambegaonkar, B. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.02.004 · Cited by 1
Eficacia y seguridad de ezetimiba en unidades de riesgo vascular
Díaz-Díaz, J. L., Tembra, M. S., Peromingo, J. A. D., Seijo, M. P., Ramonde, T. M., & Reino, A. P. (2011) · Revista Clínica Española · doi:10.1016/j.rce.2011.01.010 · Cited by 1
Using inactivating mutations to provide insight into drug action
Corbin, L. J., & Timpson, N. J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0130-x · Cited by 1
“Abbreviations CHD: Coronary heart disease; CVD: Cardiovascular disease; IMPROVE-IT: IMProved Reduction of Outcomes: Vytorin Efficacy International Trial; IMT: Intima-media thickness; LDL-C: Low-density lipoprotein cholesterol; PROVE-IT: Pravastatin or Atorvastatin Evaluation and Infection Therapy Trial; RCT: Randomize…”
BackgroundInfluentialEstudio IMPROVE-IT. Buenas noticias para ezetimiba y para los pacientes
Escobar, C., Divisón, J. A., & Díaz, M. S. (2015) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.12.003 · Cited by 1
Toth, P. P. (2015) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2015-110253 · Cited by 1
Modulation of Lipid Metabolism by Phytosterol Stearates and Black Raspberry Seed Oils
Ash, M. M. (2010) · Lincoln (University of Nebraska) · Cited by 2
Reilly, T., King, G., Park, J. H., & Tracy, A. (2010) · Europe PMC (PubMed Central) · Cited by 1
Yeboah, J., & Herrington, D. M. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.874945 · Cited by 1
Health Care Guideline Lipid Management in Adults
Woolley, T. W., Groen, S., Kofron, P. M., Leslie, S., Myers, C. D., Needham, R. H., Peters, J., Reddan, J. G., & Sorge, L. A. (2013) · Cited by 1
Primary disorders of LDL-cholesterol metabolism
Rosenson, R. S., de Ferranti, S. D., Freeman, M. W., & Saperia, G. M. (2011) · Cited by 1
Statins and Mipomersen: Mechanisms of Action and Patient Tolerability
Pang, J., Chan, D. C., & Watts, G. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_7 · Cited by 1
“2 A dv er se e ff ec ts o f m ip om er se n in P ha se I II c lin ic al tr ia ls [ 18 , 1 9 , 4 3 , 4 4 ]”
Lipid-Lowering Therapy and Apheresis: Indications and Outcomes
Moriarty, P. M., & McCalley, A. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_12 · Cited by 1
Intima-Media-Dickenmessung: Status quo et quo vadis?
Bauer, M., Mahabadi, A. A., Kälsch, H., Kara, K., Weiss, T., & Erbel, R. M. (2012) · CardioVasc · doi:10.1007/s15027-012-0084-5 · Cited by 1
Diet did not die. Just another diet study or?
Barth, J. D. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.052 · Cited by 1
Ezetimibe in the Treatment of Patients with Metabolic Diseases
Nehme, M., Upadhyay, A., & Medicine, R. I. I. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.01.55
Advances in Hypercholesterolemia
Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 3
Titus-Rains, K. S., Cantrell, M. A., Egge, J. A., Alexander, B., Shaw, R. F., & Argo, T. R. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150665 · Cited by 1
Slany, J. (2009) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-009-0723-3 · Cited by 1
How has the treatment of hypercholesterolemia in Poland changed over the last six years?
Kapłon‐Cieślicka, A., Michalak, M., Kołtowski, Ł., & Filipiak, K. J. (2017) · Cardiology Journal · doi:10.5603/cj.a2017.0047 · Cited by 1
Familial hypercholesterolemia: bridging and minding the gap in healthcare
Pang, J., Vickery, A. W., & Watts, G. F. (2013) · doi:10.2217/fmeb2013.13.24 · Cited by 1
Lardizabal, J. A., & DEEDWANIA, P. C. (2012) · doi:10.2217/ebo.11.259 · Cited by 1
Cardiovascular Disease Risk Management in Diabetes – The Implications of the REALITY Asia Study
Yan, P. C. (2008) · Asia Pacific Cardiology · doi:10.15420/apc.2008:2:1:12 · Cited by 1
Complications and Management of Chronic Kidney Disease
Tuttle, K. R. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0987-2.00011-x · Cited by 1
Chen, S., Zhao, J., Hu, J., & Guo, Z. (2017) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2017.07.15 · Cited by 1
Schroeder, E. B., & McDermott, M. T. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4975-1.00015-2 · Cited by 1
Ezetimibe in the treatment of hypercholesterolaemia
Karásek, D. (2019) · Interní medicína pro praxi · doi:10.36290/int.2019.017 · Cited by 1
Landis, M. N., & Adams, D. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-61211-1.00039-5 · Cited by 1
Genetic Disorders of Lipoprotein Metabolism
Brown, A. S., Dababneh, E. G., Chaus, A. M., Chyzhyk, V., Marinescu, V., & Pyslar, N. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_3 · Cited by 2
Familial Hypercholesterolemia: Improving Outcomes with Newer Agents
Ray, S., & Sarkar, B. (2020) · American Journal of Internal Medicine · doi:10.11648/j.ajim.20200806.17 · Cited by 1
“[13] Lastly, a small but significant rise in the incidence of cancer in SEAS trial [14] is a cause for concern.”
BackgroundHemodynamic impact of positive end expiratory pressure in right cardiac performance
Vinko Tomicic, F. (2019) · Journal of Cardiology & Current Research · doi:10.15406/jccr.2019.12.00455 · Cited by 1
Drugs that affect lipid metabolism
Nestel, P. J. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00044-1 · Cited by 1
Metadata
- Authors
- Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-04-03
- Volume
- 358
- Issue
- 14
- Pages
- 1431-1443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120289695
- Semantic Scholar
- 0da4a48a4d402878a4b01330a3e43a185140f586
- Cited by
- 1,241
- References
- 34
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 27 · 2019: 35 · 2018: 30 · 2017: 38 · 2016: 50 · 2015: 77 · 2014: 91 · 2013: 85 · 2012: 111
- FWCI
- 210.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, ezetimibe, familial hypercholesterolemia, LDL cholesterol lowering, atherosclerosis progression, carotid intima-media thickness, femoral artery, cholesterol absorption inhibition, triglycerides, C-reactive protein, statin combination therapy, lipid-lowering therapy, atherosclerotic plaque regression
- MeSH terms
- Ezetimibe, Adult, Anticholesteremic Agents, Azetidines, Carotid Arteries, Cholesterol, Double-Blind Method, Drug Therapy, Combination, Female, Femoral Artery, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Ultrasonography, Treatment Outcome, Tunica Intima, Tunica Media, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.